Document Detail

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
MedLine Citation:
PMID:  20824399     Owner:  NLM     Status:  MEDLINE    
Although allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the prognosis of patients who relapse after allogeneic HSCT has been extremely poor. Dasatinib, a second-generation tyrosine kinase inhibitor, is a promising agent for the treatment of Ph-ALL. We report on a Ph-ALL patient who relapsed early after the first allogeneic HSCT, but achieved complete molecular remission with dasatinib alone. She remains in molecular remission 12 months after the second allogeneic HSCT. Dasatinib was generally well tolerated, but she developed myalgia, nausea and positive cytomegalovirus antigenemia. In addition, sudden-onset bloody diarrhea was observed 10 days after the second HSCT, which was possibly associated with the use of dasatinib in addition to the effect of the conditioning regimen and graft-versus-host disease. In conclusion, dasatinib is an effective agent for Ph-ALL with a poor prognosis, but may be associated with specific adverse events including opportunistic infection and gastrointestinal bleeding.
Yoko Ishida; Kiriko Terasako; Kumi Oshima; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Misato Kikuchi; Shun-Ichi Kimura; Hideki Nakasone; Shinya Okuda; Shinichi Kako; Rie Yamazaki; Junji Nishida; Yoshinobu Kanda
Related Documents :
14872429 - Bleeding complications after hematopoietic stem cell transplantation.
11081389 - Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell tra...
17904879 - T cell therapy of epstein-barr virus and adenovirus infections after hemopoietic stem c...
7873999 - The hematopoietic stem cell transplantation in hodgkin's disease: questions and controv...
6410119 - A clinical trial of fibroblast transplantation for the treatment of mucopolysaccharidoses.
21042309 - Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofib...
15996249 - Renal dysfunction is a strong and independent risk factor for mortality and cardiovascu...
97399 - Effects of ethylenediaminetetraacetic acid-4 sodium solution on the surface of renal ca...
2035339 - Amoebic liver abscess: ultrasonographic characteristics and results of different therap...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2010-09-08
Journal Detail:
Title:  International journal of hematology     Volume:  92     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-06     Completed Date:  2011-01-28     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  542-6     Citation Subset:  IM    
Division of Hematology, Saitama Medical Center, Jichi Medical University, Omiya-ku, Saitama, Saitama, 330-8503, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Graft vs Host Disease / pathology,  prevention & control
Hematopoietic Stem Cell Transplantation* / adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*,  prevention & control*,  surgery
Protein Kinase Inhibitors / adverse effects,  therapeutic use*
Pyrimidines / adverse effects,  therapeutic use*
Remission Induction
Thiazoles / adverse effects,  therapeutic use*
Transplantation, Homologous
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/Thiazoles; RBZ1571X5H/dasatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patien...
Next Document:  Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.